MC

471

-0.86%↓

SANES

10.236

-1.01%↓

SAF

271.6

-3.41%↓

BBVA

18.62

-0.37%↓

BNP

89.15

-0.76%↓

MC

471

-0.86%↓

SANES

10.236

-1.01%↓

SAF

271.6

-3.41%↓

BBVA

18.62

-0.37%↓

BNP

89.15

-0.76%↓

MC

471

-0.86%↓

SANES

10.236

-1.01%↓

SAF

271.6

-3.41%↓

BBVA

18.62

-0.37%↓

BNP

89.15

-0.76%↓

MC

471

-0.86%↓

SANES

10.236

-1.01%↓

SAF

271.6

-3.41%↓

BBVA

18.62

-0.37%↓

BNP

89.15

-0.76%↓

MC

471

-0.86%↓

SANES

10.236

-1.01%↓

SAF

271.6

-3.41%↓

BBVA

18.62

-0.37%↓

BNP

89.15

-0.76%↓

Search

Sartorius Stedim Biotech.

Aperta

SettoreFinanza

161.9 -0.8

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

158.3

Massimo

163

Metriche Chiave

By Trading Economics

Entrata

-17M

47M

Vendite

67M

772M

P/E

Media del settore

68.388

39.62

Rendimento da dividendi

0.37

Margine di Profitto

6.125

Dipendenti

9,753

EBITDA

-19M

199M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+26.63% upside

Dividendi

By Dow Jones

Rendimento da dividendi

Media del settore

0.37%

4.52%

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-55M

18B

Apertura precedente

162.7

Chiusura precedente

161.9

Notizie sul Sentiment di mercato

By Acuity

20%

80%

32 / 439 Classifica in Finance

Punteggio Tecnico

By Trading Central

Fiducia

Bullish Evidence

Sartorius Stedim Biotech. Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

24 apr 2026, 00:00 UTC

Utili

Renesas Electronics 1Q Net Y68.15B Vs Net Y26.01B

24 apr 2026, 00:00 UTC

Utili

Renesas Electronics 1Q Net Y68.15B Vs Net Y26.01B

23 apr 2026, 23:47 UTC

Discorsi di Mercato

Gold Edges Lower Amid Ongoing Concerns Over Higher Inflation -- Market Talk

23 apr 2026, 23:43 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

23 apr 2026, 23:43 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

23 apr 2026, 23:43 UTC

Discorsi di Mercato

Nikkei May Decline Amid Uncertainty Over U.S.-Iran Conflict -- Market Talk

23 apr 2026, 23:13 UTC

Acquisizioni, Fusioni, Takeovers

Trump on Spirit Airlines: 'I Think We'd Just Buy It' -- Update

23 apr 2026, 22:33 UTC

Utili

Intel Shares Jump 20% as AI Agents Drive Big Growth -- WSJ

23 apr 2026, 22:17 UTC

Utili

PLS Executed Offtake Agreement With Ronbay

23 apr 2026, 22:17 UTC

Utili

PLS Secured Up to A$38.1M in Australia Government ARENA Grant Funding

23 apr 2026, 22:16 UTC

Utili

PLS Commences Commissioning of Midstream Demonstration Plant

23 apr 2026, 22:15 UTC

Utili

PLS Group Reaffirms FY26 Guidance for All Metrics

23 apr 2026, 22:14 UTC

Utili

PLS Group 3Q Cash Margin From Operations A$461M at March 31

23 apr 2026, 22:14 UTC

Utili

PLS Group 3Q Cash Balance A$1.455 Billion at March 31

23 apr 2026, 22:13 UTC

Utili

PLS Group 3Q Unit Operating Cost A$733/Ton CIF, Up 2% on 2Q

23 apr 2026, 22:12 UTC

Utili

Correct: PLS Group 3Q Unit Operating Cost A$520/Ton FOB, Down 11% on 2Q

23 apr 2026, 22:12 UTC

Utili

PLS Group 3Q Unit Operating Cost US$520/Ton FOB, Down 11% on 2Q

23 apr 2026, 22:11 UTC

Utili

PLS Group 3Q Realized Price US$1,867/Ton, Up 61% on 2Q

23 apr 2026, 22:10 UTC

Utili

PLS Group 3Q Revenue A$567,000, Up 52% on 2Q

23 apr 2026, 22:09 UTC

Utili

PLS Group 3Q Sales 195,700 Tons, Down 16% on 2Q

23 apr 2026, 22:08 UTC

Utili

PLS Group 3Q Production 232,400 Tons, Up 12% on 2Q

23 apr 2026, 22:04 UTC

Utili

Intel Sales Rise 7% as AI Agents Drive Growth -- WSJ

23 apr 2026, 21:56 UTC

Discorsi di Mercato
Utili

Intel Points to Growing Role of CPUs Amid AI Shifts -- Market Talk

23 apr 2026, 21:48 UTC

Acquisizioni, Fusioni, Takeovers

Regeneron Shares Up on Trump Drug Pricing Deal -- Barrons.com

23 apr 2026, 21:27 UTC

Utili

Intel CFO: All Demand Signals Point to Growing Role of CPUs in AI Era

23 apr 2026, 21:25 UTC

Utili

Intel CFO Expects Factories to Continue Increasing Supply in 3Q, 4Q, but at More Measured Pace Than Previously Expected

23 apr 2026, 21:24 UTC

Utili

SAP Stock Rebounds From Software Slaughter. The Cloud Boosted Europe's Tech Titan. -- Barrons.com

23 apr 2026, 21:24 UTC

Utili

Blackstone Stock Falls After Earnings. Private Credit Remains in Focus. -- Barrons.com

23 apr 2026, 21:21 UTC

Utili

Intel to Look for Unconventional Way to Boost Manufacturing Capacity Through Musk's Terafab Project, CEO Says

23 apr 2026, 21:21 UTC

Utili

Intel CEO: He, Elon Musk Believe Global Semiconductor Supply Isn't Keeping Up With Accelerating Demand

Confronto tra pari

Modifica del prezzo

Sartorius Stedim Biotech. Previsione

Obiettivo di Prezzo

By TipRanks

26.63% in crescita

Previsioni per 12 mesi

Media 233 EUR  26.63%

Alto 262 EUR

Basso 210 EUR

Basato su 8 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Sartorius Stedim Biotech. - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

8 ratings

7

Acquista

1

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

202.7 / 211.7Supporto e resistenza

A breve termine

Bullish Evidence

A termine intermedio

Strong Bullish Evidence

A lungo termine

Strong Bullish Evidence

Sentiment

By Acuity

32 / 439 Classifica in Finanza

Notizie sul Sentiment di mercato

Prove rialziste molto forti

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sopra la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Sartorius Stedim Biotech.

Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides cell cultivation, fermentation, separation, purification, and fluid management services; biolayer interferometry instruments; microbiology enumeration, sterility testing, and air monitoring instruments; pipette products; sensors and analyzers; biomolecule analysis tools; flow cytometry; batch and intensified chromatography systems; lab data and fleet management software; live cell imaging and analysis; surface plasmon resonance solutions; and weighing products. In addition, the company offers data analytics software for modeling and optimizing processes of biopharmaceutical development and production; process automation platform and software; and develops and produces transfection, as well as other DNA/RNA delivery reagents and plasmid DNA. It serves manufacturers of medications, vaccines, foods, and chemicals, as well as research and development laboratories. The company was incorporated in 1978 and is headquartered in Aubagne, France. As of December 31, 2023, Sartorius Stedim Biotech S.A. operates as a subsidiary of Sartorius AG.
help-icon Live chat